Felbamate

Also known as: Felbamato, Felbamaturis

Drug #1455

Felbamate is a carbamate structurally related meprobamate. Felbamate is used in the treatment of epilepsy. Felbamate is used alone or in combination with other agents for refractory partial seizures with or without secondary generalisation.

← Previous drug Next drug →

Primary Characteristics

Felbamate is also known as Felbamato, Felbamaturis.

It is of Synthetic origin.

Molecular Weight: 238.24 · Solubility in Water: 0.33 gm/l · Solubility in Alcohol: 5 gm/l · Non-proprietary name: Felbamate.

Pharmacokinetics

Distribution: Felbamate has a volume of distribution is 0.76l/kg. plasma protein binding is 22 - 25 %.

Elimination: it is metabolised via Liver, plasma half-life is 16 - 23 hr, renal excretion is 756 +/- 82 mcg/kg.

Indications

Felbamate is primarily indicated in conditions like Partial seizures, Seizures associated with lennox gastaut syndrome.

Contraindications

Felbamate is contraindicated in conditions like Blood dyscrasias, Bone marrow depression, Hepatic dysfunction, Hypersensitivity.

Dosage

Felbamate's dosage details are as follows:

Dose	Single Dose	Frequency	Route
Adult Dosage
3.6 g	3.6 g	Every 6h	PO
Paediatric Dosage (20kg)
15 mg/kg	15 mg/kg	Every 4h
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown4 interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Felbamate in overdosage may give rise to further complications which include Stevens johnson syndrome , Stevens johnson syndrome .

Felbamate produces potentially life-threatening effects which include Aplastic Anemia , Hepatic failure, Aplastic anemia. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Felbamate are Impaired breathly, Gastric distress, Increased heart rate.

Felbamate is known to cause more or less tolerable side effects which are usually transient. These include Anorexia , Dizziness, Headache, Hypokalemia , Hypophosphatemia, Insomnia, Nausea, Somnolence , Vomiting .

Warnings / Precautions

Complete blood counts and liver function tests should be carried out before the patient starts treatment and regularly during tretament. The drug should be discontinued if there is any evidence of bone marrow deppressio or liver abnormalities. Take protective measures against exposure to UV radiation because drug may cause photosensitivity reaction. Also with renal impairment.

Available Brands

None recorded.

Storage Conditions

Felbamate should be stored Tab, Susp.

Drug Classification

1.5 — Anticonvulsants and Antiepileptics